CD274 and head and neck squamous cell carcinoma: On the basis of KEYNOTE-048, pembrolizumab monotherapy or in combination with chemotherapy has supplanted the EXTREME regimen as the first line therapy in patients with R/M HNSCC, especially in PD-L1 expressing tumors.